Drugs.com
JUNE 1, 2024
SATURDAY, June 1, 2024 -- Can mindfulness meditation be good medicine for both mental and physical ills? Yes, says one expert who explains the practice and what conditions it might help. A particular form of mindfulness that focuses on pleasure.
Twist Bioscience
JUNE 1, 2024
Jeff Goldberg, CEO Our platform rapidly generates and validates new targets for treating challenging cancers. Working with Abveris will enable us to quickly identify and select highly specific antibodies for those targets, so that we can take the best antibody forward to address the needs of particular patient populations.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
JUNE 1, 2024
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Slovakia.
Perficient: Drug Development
JUNE 1, 2024
Permission sets in Salesforce are a powerful tool for granting users access to specific objects, fields, and functionality without modifying their profiles. However, testing permission sets is crucial to ensure they are working as intended and not causing any unintended consequences. Let’s discuss when and how to test permission sets, as well as some advanced techniques for more thorough testing. 1.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Drug Patent Watch
JUNE 1, 2024
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five… Source
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Patent Watch
JUNE 1, 2024
Brivaracetam is the generic ingredient in two branded drugs marketed by Ucb Inc, Aurobindo Pharma Ltd, Lupin Ltd, Sunshine, and Zydus Pharms and, and is included in seven NDAs.
Twist Bioscience
JUNE 1, 2024
ROBERT CARNAHAN, PHD Twist is the only synthetic DNA provider who can deliver the quantity and quality of DNA we need for our projects rapidly. We are working with them not only as a vendor for synthetic genes and antibodies, but have expanded our relationship to leverage the Twist Biopharma capabilities, which we believe complement our antibody discovery efforts.
Drug Patent Watch
JUNE 1, 2024
Annual Drug Patent Expirations for NUZYRA Nuzyra is a drug marketed by Paratek Pharms Inc and is included in two NDAs. It is available from one supplier.
Expert insights. Personalized for you.
234 
Let's personalize your content